---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-102899"
form_type: "8-K"
ticker: "ESLA"
cik: "0001844417"
company_name: "Estrella Immunopharma, Inc."
filed_at: "2024-11-26T23:59:59+00:00"
generated_at: "2026-05-29T18:05:35.576581+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Estrella Immunopharma changes fiscal year end to Dec 31, transition period Jul-Dec 2024

## Summary
- Board approved fiscal year change from June 30 to December 31 effective November 25, 2024.
- Transition period covers July 1, 2024 through December 31, 2024.
- Company will file Form 10-KT with audited financials for the transition period.

## SEC filing metadata
- accession: 0001213900-24-102899
- form_type: 8-K
- ticker: ESLA
- cik: 0001844417
- company_name: Estrella Immunopharma, Inc.
- filed_at: 2024-11-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1844417/000121390024102899/0001213900-24-102899-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1844417/000121390024102899/ea0222615-8k_estrella.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-102899
- JSON: https://secwatch.observer/filing/0001213900-24-102899.json
- Plain text: https://secwatch.observer/filing/0001213900-24-102899.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.